Adrien brings to Orchard Therapeutics more than 15 years of experience growing pharma and biotech businesses via in- and out-licensing, M&A and portfolio development.
Prior to joining Orchard, Adrien was Executive Director, Corporate Strategy and Development at AstraZeneca where he was leading M&A activities as well as successful out-licensing and new companies spin-off projects. He was a member of the Board of Directors of Corvidia Therapeutics.
Prior to AstraZeneca, Adrien spent 9 years at GSK and his most recent experience was Strategy & Operations Director in the Rare Diseases Unit, where he worked in particular on the in-licensing of the TIGET (the Telethon Institute of Gene Therapy) autologous gene therapy portfolio and other successful business development activities. He was a member of the Advisory Committee for Kurma BioFund II, a venture capital fund with a special focus on rare diseases.
His experience at GSK also encompasses European and global roles of increasing seniority in R&D portfolio strategy and commercial analysis. He started his career as a strategy consultant at Alcimed (Paris, France), supporting the development of biotechnology start-up companies. Adrien holds an Engineering Degree from Supélec (Paris, France) and a MSc in Engineering and Physical Science in Medicine from Imperial College (London, UK).